Abstract: An electrostatic discharge protection device including the following components is provided. A first PNP BJT includes a P-type region, first and second N-type well regions, first P-type, first N-type, and second P-type doped regions, and an N-type region. An NPN BJT includes first P-type and third N-type well regions, a second N-type doped region, a third P-type doped region, and a third N-type doped region. A second PNP BJT includes the first P-type and third N-type well regions, the third P-type doped region, the third N-type doped region, and a fourth P-type doped region. The second P-type doped region, the first N-type doped region, the third N-type doped region, and the fourth P-type doped region are coupled to a high voltage side terminal. The first P-type doped region, the second N-type doped region, and the third P-type doped region are coupled to a low voltage side terminal.

Abstract: An electrostatic discharge protection device including the following components is provided. A first PNP BJT includes a P-type region, first and second N-type well regions, first P-type, first N-type, and second P-type doped regions, and an N-type region. An NPN BJT includes first P-type and third N-type well regions, a second N-type doped region, a third P-type doped region, and a third N-type doped region. A second PNP BJT includes the first P-type and third N-type well regions, the third P-type doped region, the third N-type doped region, and a fourth P-type doped region. The second P-type doped region, the first N-type doped region, the third N-type doped region, and the fourth P-type doped region are coupled to a high voltage side terminal. The first P-type doped region, the second N-type doped region, and the third P-type doped region are coupled to a low voltage side terminal.

Abstract: Aspects of the present disclosure include G6PD-modulating agents and methods for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample using such agents. A G6PD-modulating agent can be dimeric and include two terminal carbocyclic or heterocyclic groups connected via a linker. In some instances, the agent includes a diamino-containing linker. In certain cases, the agent includes two amino substituents. Also provided are methods for treating a subject for a G6PD deficiency-associated condition, that include administering to a subject an effective amount of a G6PD-modulating agent to selectively activate a mutant G6PD and treat the subject. Kits and compositions for practicing the subject methods are also provided.

Abstract: The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an individual undergoing radiotherapy for head and neck cancer.

Abstract: The present disclosure provides methods of protecting and expanding hematopoietic cells. The present disclosure also provides methods of increasing the potency of hematopoietic cells. Aspects of the methods include contacting a starting population of hematopoietic cells with a therapeutically effective amount of at least one ALDH2 agonist. Aspects include in vivo, in vitro and ex vivo methods of protecting, expanding and increasing the potency of hematopoietic cells. Aspects of the methods include treating an individual who is undergoing chemotherapy or radiation treatment for cancer, has been exposed to damaging toxins, has a genetic disease that leads to HSC damage, bone marrow failure, an autoimmune disease, or development of hematologic malignancies. Aspects of the methods also include treating a healthy individual who is a stem cell transplant donor.

Abstract: The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Abstract: The present disclosure provides methods of increasing proliferation of adult salivary stem cells, methods of protecting adult salivary stem cells and improving salivary gland function. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with a therapeutically effective amount of at least one isolated monoterpene and subjecting the adult salivary stem cells to radiation treatment. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells and improve salivary gland function in an individual undergoing radiotherapy for head and neck cancer. The methods also include treating an individual with dry eye with a therapeutically effective amount of at least one isolated monoterpene.

Abstract: The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Abstract: The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Abstract: Methods and compositions are provided for treating pain in an individual. Aspects of the methods include administering to the individual an agent that promotes ALDH activity. These methods find many uses, for example in treating and preventing nociceptive pain, inflammatory pain, and neuropathic pain.

Abstract: The present invention discloses an electrostatic discharge protection circuit, comprising a diode and a N-type metal-oxide-semiconductor (NMOS) transistor. The diode locating on a N-well comprises an high P-doping concentration region and an nonadjacent high N-doping concentration region. The NMOS transistor, locating on a P-well, comprises a drain, a source and a gate, and the drain and the source are formed by the high N-doping concentration region. Wherein the P-well further comprises a high P-doping concentration region near the source, the drain of the NMOS is electrically connected to the high N-doping concentration region of the diode, the source of the NMOS and the adjacent high P-doping concentration region are electrically connected to a ground, the gate of the NMOS transistor electrically connected to a trigger point.

Abstract: The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.

Abstract: The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition.

Abstract: The present disclosure provides compounds of formula (I) that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity, and methods of preparing these compounds.

Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.

Abstract: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.

Abstract: An electronic apparatus and an electronic fuse (e-fuse) thereof are provided. The e-fuse includes a transistor and a voltage selector. A first end of the transistor receives a power voltage, and a second end of the transistor is coupled to a reference ground voltage. The voltage selector receives a programming voltage and a read voltage, and outputs the programming voltage or the read voltage to a control end of the transistor according to a control signal. Wherein, the control signal is used to indicate the e-fuse being operated in a programming mode or a read mode. When the e-fuse is operated in the programming mode, the programming voltage is provided to the control end of the transistor for damaging a gate oxide layer of the transistor.

Abstract: An electrostatic discharge protection device has a substrate, a P-well, a N-well, and an isolation portion. The P-well and N-well formed in the substrate are neighboring to each other. Along a specific direction, the P-well has a first N-type, a first P-type, a second N-type, a second P-type, and a third N-type high doping regions sequentially located thereon, and the N-well has a third P-type, a fourth N-type, a fourth P-type, a fifth N-type, and a fifth P-type high doping regions sequentially located thereon. The first N-type, the third N-type, the first P-type, and the second P-type high doping regions are coupled to a ground end, the third P-type, the fifth P-type, the fourth N-type, and the fifth N-type high doping regions are coupled to a voltage supply end, and the second N-type and the fourth P type high doping regions are coupled to an input/output end.

Abstract: Compositions and methods are provided for treating or preventing a parasitic disease in a subject. Aspects of the methods include administering an ALDH antagonist to a subject that is infected with a parasite or that is at risk for being infected with a parasite. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.

Abstract: An electrostatic discharge protection device is disclosed. The electrostatic discharge protection device comprises a N+ well, a P doping region, a first N doping region, a plurality of N sub-doping regions, a first N+ doping region, a first P+ doping region, a second N+ doping region, and a second doping region. The P doping region is disposed in the N+ well. The first N doping region is disposed in the P doping region. The plurality of N sub-doping regions is disposed in parallel in the P doping region. The first N+ doping region is disposed in the first N doping region. The first P+ doping region is disposed in the first N doping region. The second N+ doping region is disposed in the P doping region.